Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection Bei Jiang, Leijie Wang, Huan Liu, Lin Wang, Rui Su, Liang Xu, Guochao Wei, Jia Li, Fengmin Lu, Xiangmei Chen Journal of Medical Virology.2024;[Epub] CrossRef
Backgrounds/Aims The objective of our study was to determine the epidemiological, laboratory, and serological characteristics of patients with chronic hepatitis B virus (HBV) infection and normal transaminases. The study also aimed to evaluate liver damage by measuring the liver fibrosis (LF) grade and to identify possible factors associated with the presence of fibrosis.
Methods A retrospective observational study was conducted in patients with chronic HBV infection and classified as inactive carriers or immune-tolerant. Epidemiological variables of age, sex, immigrant, alcohol consumption, and body mass index (BMI), as well as virological variables (HBV DNA) and transaminase level were collected throughout the follow-up. The LF grade was evaluated by transient elastography. The cutoff value for significant fibrosis (SF) was liver stiffness ≥7.9 kPa.
Results A total of 214 patients were included in the analysis, and 62% of them had a BMI ≥25 kg/m2 . During follow-up, 4% of patients showed transaminase elevation (<1.5 times normal). Most patients had a viral DNA level <2,000 IU/mL (83%). Data on LF were available in 160 patients; of these, 14% had SF, 9% F3, and 6% F4. The variables associated with the presence of SF were transaminase alteration during follow-up, as 23% of patients with SF had elevated transaminases versus 3% of patients without SF (P<0.005), and BMI, as the vast majority of patients with SF (88%) had a BMI ≥25 kg/m2 versus 56% of patients without SF (P<0.05).
Conclusions In patients with chronic HBV infection and normal transaminases, liver damage does not seem to be related to DNA levels, alcohol consumption, or immigrant status. SF seems to be associated with transaminase alteration during follow-up and elevated BMI. It is therefore recommended to measure LF grade with validated non-invasive methods in such patients.
Citations
Citations to this article as recorded by
Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients Chinmay Bera, Nashla Hamdan-Perez, Keyur Patel Journal of Clinical Medicine.2024; 13(4): 1046. CrossRef
Dynamic Changes in Liver Stiffness in Patients with Chronic Hepatitis B Undergoing Antiviral Therapy Alin Lazar, Ioan Sporea, Alexandru Popa, Raluca Lupusoru, Diana Gherhardt, Ruxandra Mare, Alexandru Apostu, Madalina Hnatiuc, Roxana Șirli Diagnostics.2022; 12(11): 2646. CrossRef
The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma Nicole Laurencia Yuwono, Kristina Warton, Caroline Elizabeth Ford eLife.2021;[Epub] CrossRef
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim Clinical and Molecular Hepatology.2021; 27(2): 295. CrossRef
Use of bile acids as potential markers of liver dysfunction in humans Samy A. Azer, Rana Hasanato Medicine.2021; 100(41): e27464. CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim Journal of Korean Medical Science.2021;[Epub] CrossRef
Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co‐infected Adults Richard K. Sterling, Wendy C. King, Abdus S. Wahed, David E. Kleiner, Mandana Khalili, Mark Sulkowski, Raymond T. Chung, Mamta K. Jain, Mauricio Lisker‐Melman, David K. Wong, Marc G. Ghany Hepatology.2020; 71(2): 411. CrossRef
Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir Tae Seop Lim, Hyun Woong Lee, Jung Il Lee, In Hee Kim, Chang Hun Lee, Byoung Kuk Jang, Woo Jin Chung, Hyung Joon Yim, Sang Jun Suh, Yeon Seok Seo, Han Ah Lee, Jung Hwan Yu, Jin‐Woo Lee, Sang Gyune Kim, Young Seok Kim, Soo Young Park, Won Young Tak, Soon S Journal of Viral Hepatitis.2020; 27(10): 1052. CrossRef
A different detection method reveals a new role of alanine aminotransferase as an indicator of liver fibrosis Pil Soo Sung The Korean Journal of Internal Medicine.2020; 35(2): 295. CrossRef
Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level
Mi Young Jeon, Beom Kyung Kim, Seung Up Kim Clinical and Molecular Hepatology.2018; 24(4): 367. CrossRef
Background/Aims The aim of this study was to establish the characteristics of children with hepatitis B
e antigens (HBeAg) positive chronic hepatitis B who were cleared of hepatitis B surface antigens (HBsAg) as
a result of lamivudine treatment. Methods: Seventy-six children with chronic hepatitis B who were
seropositive for HBeAg were treated with lamivudine for at least 6 months. HBeAg seroconversion occurred
during treatment in 49 of these children, who were then followed up to assess their clearance of serum HBsAg.
Various clinical variables were compared between those patients who were cleared of HBsAg and those who
were not, including age, pretreatment serum levels of alanine aminotransferase (ALT) and hepatitis B virus
(HBV) DNA, treatment duration, the time elapsed between initiation of treatment and ALT normalization, HBV
DNA negativization, HBeAg seroconversion, and HBsAg clearance. Results: HBsAg disappeared in 13 of the
49 (26.5%) patients who experienced lamivudine-induced HBeAg seroconversion; HBsAg did not reappear
during follow-up period (1-86 months). The time that elapsed between initiation of lamivudine treatment and
total HBsAg clearance was 25.9±27.1 months (mean±SD; range: 5-104 months). The age at which treatment
was initiated was the only factor associated with HBsAg clearance. Children who were cleared of HBsAg were
significantly younger than those who were not (5.1±4.3 years vs. 7.9±4.9 years, respectively; P=0.006). All
13 of these patients eventually produced antibodies to HBsAg. Conclusions: Younger children (age <7 years
old) have a higher chance of HBsAg clearance than older children after the treatment of HBeAg-positive
chronic hepatitis B with lamivudine. (Korean J Hepatol 2009;15:168-178)
Citations
Citations to this article as recorded by
Predictive value of HBeAg titer dynamics for HBsAg clearance in pediatric chronic hepatitis B Sukjin Hong, Jun Hyun Hwang, Keumoung Kim, Younghae Do, Naeun Kwak, Hyo Rim Suh, Sujin Choi, Ben Kang, Byung-Ho Choe Frontiers in Pediatrics.2025;[Epub] CrossRef
Insights into the Natural and Treatment Courses of Hepatitis B in Children: A Retrospective Study Lorenza Forna, Laura Bozomitu, Ancuta Lupu, Vasile Valeriu Lupu, Camelia Cojocariu, Carmen Anton, Irina Girleanu, Ana Maria Singeap, Cristina Maria Muzica, Anca Trifan Biomedicines.2024; 12(7): 1585. CrossRef
Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries Ben Kang, Dae Yong Yi, Byung-Ho Choe Frontiers in Pediatrics.2022;[Epub] CrossRef
Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B Jae Young Choe, Jae Sung Ko, Byung-Ho Choe, Jung Eun Kim, Ben Kang, Kyung Jae Lee, Hye Ran Yang Journal of Korean Medical Science.2018;[Epub] CrossRef
Current Role of Lamivudine Regarding Therapeutic Response and Resistance in Children with Chronic Hepatitis B Suk Jin Hong, Yeo Hyang Kim, Byung-Ho Choe, Hyo Jung Park, Won-Young Tak, Young-Oh Kweon Pediatric Gastroenterology, Hepatology & Nutrition.2013; 16(2): 80. CrossRef
Chang Mo Moon, M.D., Do Young Kim, M.D., Ki Jun Song, Ph.D.1, Ja Kyung Kim, M.D.,
Hyun Woong Lee, M.D., Jung Min Lee, M.D., Ki Tae Yoon, M.D., Yong Han Paik, M.D.,
Dong Ki Kim, Ph.D.1, Kwang-Hyub Han, M.D., Chae Yoon Chon, M.D., Young Myoung Moon, M.D.,
and Sang Hoon Ahn, M.D.
Background/Aims The long-term virologic and biochemical changes in patients with HBeAg negative HBV infection, especially in Asia, remain unclear. To address this issue, we conducted a 3 year- retrospective, cohort study. Methods: A total of 157 patients with HBeAg negative HBV infection who were monitored without treatment were reviewed between January 1999 and March 2004. Those patients were followed up every 3 months with liver function tests and serologic tests. All patients were stratified into 3 groups; inactive carrier (IC), viremic carrier (VC) and chronic hepatitis (CH). Serum HBV DNA was measured by a hybridization assay (sensitivity: 1.4×105 genomes/mL, Digene Diagnostics, Silver Spring, USA). Results: The median age of enrolled patients was 42.7 years (M:F=2.3:1). By single time-point observations, the 3 year-cohort prevalence of HBeAg negative CH varied from 12.7 to 35.8% (median 20.7%) HBeAg negative CH was accumulated over time (P=0.002) and transition rates among three groups after 3 years of follow-up are as follows: IC to CH, 6.0%; IC to VC, 4.1%; VC to CH, 23.2%. VC seems to be a disease state in the middle of transition from IC to CH. Conclusions: We demonstrated the dynamic changing patterns of HBeAg negative CH with time, of which the change from IC or VC to CH was dominant. (Korean J Hepatol 2006;12:163-172)
First
Prev
